Characterization of a shorter recombinant polypeptide chain of XXXX on osteoblast behaviour.

@entity3534 @entity8087 @entity1841 @entity12502 @entity622 @entity623
BACKGROUND: Recombinant bone morphogenetic protein two (rhBMP2) has been utilised for a variety of clinical applications in orthopaedic surgery and dental procedures. Despite its widespread use, concerns have been raised regarding its short half-life and transient bioactivity in vivo. Recent investigation aimed at developing rhBMP2 synthesized from a shorter polypeptide chain (108 @entity3534 ) has been undertaken. METHODS: The osteopromotive properties of @entity1841 were investigated on cell behaviour. Five concentrations of rhBMP2_108 including 10, 50, 100, 200 and 500  ng/ml were compared to a commercially available rhBMP2 (100  ng/ml). Each of the working concentrations of rhBMP2_108 were investigated on MC3T3-E1 osteoblasts for their ability to induce osteoblast recruitment, proliferation and differentiation as assessed by @entity623 ( @entity623 ) staining, @entity622 staining, and real-time PCR for genes encoding @entity623 , @entity12502 ( @entity12502 ), collagen-1 (COL-1) and @entity8087 . RESULTS: The results demonstrate that all concentrations of rhBMP2_108 significantly improved cell recruitment and proliferation of osteoblasts at 5  days post seeding. Furthermore, rhBMP2_108 had the most pronounced effects on osteoblast differentiation. It was found that rhBMP2_108 had over a four fold significant increase in @entity623 activity at seven and 14  days post-seeding and the concentrations ranging from 50 to 200  ng/ml demonstrated the most pronounced effects. Analysis of real-time PCR for genes encoding @entity623 , @entity12502 , COL-1 and @entity8087 further confirmed dose-dependant increases at 14  days post-seeding. Furthermore, @entity622 staining demonstrated a concentration dependant increase in staining at 14  days. CONCLUSION: The results from the present study demonstrate that this shorter polypeptide chain of rhBMP2_108 is equally as bioactive as commercially available rhBMP2 for the recruitment of progenitor cells by facilitating their differentiation towards the osteoblast lineage. Future in vivo study are necessary to investigate its bioactivity.
